OptimizeRx (NASDAQ:OPRX) Lowered to "Hold" Rating by Zacks Research

Key Points

• Zacks Research downgraded OptimizeRx (OPRX) from "strong-buy" to "hold," and several brokers cut price targets on March 6, though MarketBeat's consensus remains a Moderate Buy with an average price target of $17.57.
• Shares opened at $6.63 with a market capitalization of $124.4M and a P/E of 25.5, trading below its 200‑day moving average ($11.40) and substantially under the consensus price target.
• The board approved a $10.0M share repurchase plan (up to 6.8% of shares), and the company reported quarterly EPS of $0.51 with a net margin of 4.69%.

OptimizeRx (NASDAQ:OPRX - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. B. Riley Financial restated a "buy" rating and issued a $11.00 target price (down from $28.00) on shares of OptimizeRx in a research note on Friday, March 6th. Stifel Nicolaus dropped their target price on OptimizeRx from $21.00 to $17.00 and set a "buy" rating on the stock in a research note on Friday, March 6th. Lake Street Capital reduced their target price on OptimizeRx from $24.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, March 6th. Roth Mkm decreased their price target on OptimizeRx from $32.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, March 6th. Finally, Stephens dropped their price target on OptimizeRx from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, OptimizeRx has a consensus rating of "Moderate Buy" and an average price target of $17.57.

OptimizeRx Price Performance

OPRX opened at $6.63 on Monday. The firm has a market capitalization of $124.38 million, a PE ratio of 25.50 and a beta of 1.19. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.04 and a quick ratio of 3.04. The business's 50-day moving average is $6.71 and its two-hundred day moving average is $11.40. OptimizeRx has a 1 year low of $5.54 and a 1 year high of $22.25.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. Research analysts anticipate that OptimizeRx will post 0.5 earnings per share for the current fiscal year.

OptimizeRx declared that its Board of Directors has approved a share repurchase plan on Thursday, March 5th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Institutional Trading of OptimizeRx

Several large investors have recently made changes to their positions in OPRX. Quantbot Technologies LP acquired a new position in OptimizeRx in the 2nd quarter valued at $44,000. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock worth $55,000 after purchasing an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of OptimizeRx during the fourth quarter worth $62,000. Aaron Wealth Advisors LLC acquired a new stake in shares of OptimizeRx in the first quarter valued at about $66,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of OptimizeRx in the first quarter valued at about $85,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.